Physician profile
Judy L Bourget
NPI 1073593240
$2,367.90
in general payments reported to CMS, 2019-2025
15 companies · $521 in 2025
The $521 reported for 2025 was more than what 84% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $47.47 · 2021: $199 · 2022: $475 · 2023: $425 · 2024: $574 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $457.12 | 2022-2024 | |
| Merz North America, INC. | $358.50 | 2021-2024 | Xeomin |
| Abbvie INC. | $318.73 | 2024-2025 | |
| Lilly USA, LLC | $310.31 | 2022-2025 | Mounjaro, Kisunla, Amyvid |
| Corcept Therapeutics | $308.86 | 2024-2025 | Korlym |
| Inari Medical, INC. | $208.61 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novo Nordisk INC | $207.77 | 2019-2024 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $44.77 | 2021 | |
| Exact Sciences Corporation | $25.49 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $22.58 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $21.81 | 2024 | Gemtesa |
| Galderma Laboratories, L.P. | $21.30 | 2021 | |
| Acella Pharmaceuticals, LLC | $21.21 | 2023 | NP Thyroid 60 |
| Astellas Pharma US INC | $21.18 | 2024 | Veozah |
| Revance Therapeutics, INC. | $19.66 | 2024 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judy Bourget listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.